Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients : A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland

Show full item record



Permalink

http://hdl.handle.net/10138/330200

Citation

Vuorinen , A-L , Lehto , M , Niemi , M , Harno , K , Pajula , J , van Gils , M & Lahteenmaki , J 2021 , ' Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients : A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland ' , Clinical Epidemiology , vol. 13 , pp. 183-195 . https://doi.org/10.2147/CLEP.S289031

Title: Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients : A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland
Author: Vuorinen, Anna-Leena; Lehto, Mika; Niemi, Mikko; Harno, Kari; Pajula, Juha; van Gils, Mark; Lahteenmaki, Jaakko
Contributor: University of Helsinki, Staff Services
University of Helsinki, HUSLAB
Date: 2021
Language: eng
Number of pages: 13
Belongs to series: Clinical Epidemiology
ISSN: 1179-1349
URI: http://hdl.handle.net/10138/330200
Abstract: Purpose: To assess the association between VKORC1 and CYP2C9 variants and the incidence of adverse drug reactions in warfarin-treated patients in a real-world setting. Materials and Methods: This was a register-based cohort study (PreMed) linking data from Finnish biobanks, national health registries and patient records between January 1st 2007 and June 30th 2018. The inclusion criteria were: 1) >= 18 years of age, 2) CYP2C9 and VKORC1 genotype information available, 3) a diagnosis of a cardiovascular disease, 4) at least one warfarin purchase, 5) regular INR tests. Eligible individuals were divided into two warfarin sensitivity groups; normal responders, and sensitive and highly sensitive responders based on their VKORC1 and CYP2C9 genotypes. The incidences of clinical events were compared between the groups using Cox regression models. Results: The cohort consisted of 2508 participants (45% women, mean age of 69 years), of whom 65% were categorized as normal responders and 35% sensitive or highly sensitive responders. Compared to normal responders, sensitive and highly sensitive responders had fewer INR tests below 2 (median: 33.3% vs 43.8%, 95% CI: - 13.3%, - 10.0%) and more above 3 (median: 18.2% vs 6.7%, 95% Cl: 8.3%, 10.8%). The incidence (per 100 patient-years) of bleeding outcomes was 5.4 for normal responders and 5.6 for the sensitive and highly sensitive responder group (HR=1.03, 95% CI: 0.74, 1.44). The incidence of thromboembolic outcomes was 4.9 and 7.8, respectively (HR=1.48, 95% CI: 1.08, 2.03). Conclusion: In a real-world setting, genetically sensitive and highly sensitive responders to warfarin had more high INR tests and required a lower daily dose of warfarin than normal responders. However, the risk for bleeding events was not increased in sensitive and highly sensitive responders. Interestingly, the risk of thromboembolic outcomes was lower in normal responders compared to the sensitive and highly sensitive responders.
Subject: pharmacogenomics
warfarin
bleeding
INR
CYP2C9
VKORC1
ADVERSE DRUG EVENTS
HEMORRHAGIC COMPLICATIONS
VKORC1 GENOTYPES
RISK-FACTORS
ASSOCIATION
VARIANTS
OUTCOMES
THERAPY
QUALITY
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
clep_289031_pha ... d_clinical_events_in_w.pdf 1.141Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record